ReviewMedicine2026
Literature review of myasthenia gravis complicated by myocardial damage.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMyasthenia gravis (MG) is a chronic autoimmune disorder predominantly driven by pathogenic autoantibodies directed against postsynaptic acetylcholine receptors, impairing neuromuscular transmission. Although cardiovascular complications remain relatively uncommon among MG patients, their emergence markedly elevates the risk of fatal outcomes. This review synthesizes existing evidence to delineate the clinical manifestations of MG-associated myocardial damage, offering clinicians a comprehensive framework for early detection and evidence-based therapeutic intervention.
methodsWe analyzed 84 cases of myasthenia gravis associated with myocardial damage from the database and comprehensively evaluated their clinical characteristics.
resultsThe average age of patients presenting with myasthenia gravis and concurrent myocardial damage was 64.5 years. Cardiac complications predominantly included myocarditis, takotsubo cardiomyopathy, acute myocardial infarction, and coronary spastic angina. Serological analysis revealed 2 principal autoantibodies: acetylcholine receptor (AChR) antibody and anti-titin antibody. Clinical outcomes demonstrated a 72.6% survival rate alongside a 23.8% case fatality rate. These variables were more frequently observed among fatal cases but were not statistically associated with mortality: AChR antibody positivity, thymoma, myocarditis, immune checkpoint inhibitor use, and acute myocardial infarction.
conclusionThis study represents the inaugural comprehensive analysis examining the association between myasthenia gravis and concurrent cardiac injury. Our research elucidates potential pathophysiological pathways underlying this clinical entity. These findings highlight the need for clinical awareness and screening of myocardial involvement in MG patients and may provide preliminary evidence for future consensus development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.